In this prospective, open-label, non-controlled, clinical trial, researchers analyzed 49 candidates to estimate the 4-year consequences of aflibercept in treatment-resistant neovascular age-related macular degeneration (nAMD). They calculated best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height and geographic atrophy (GA) surface area. They observed a reduction in CRT from baseline, 170.3 ± 143.3 μm with the absence of macular fluid in 56% of eyes at the end of 48 months. A decline in PED by a mean 77.5 ± 20.0 μm whereas an incline in geographic atrophy by a mean of 4.1 ± 3.4 mm2 was noted over the 48 months. They concluded aflibercept, efficient alternative therapy as good anatomical and stable functional responses were achieved.

Read the full article on Acta Ophthalmologica

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *